Granisetron: A Pharmacoeconomic Evaluation of its Use in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

PharmacoEconomics

Volumn 9, Issue 4, 1996, Pages 357-374

  Plosker, Greg L ^a   Benfield, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GRANISETRON; ONDANSETRON;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VOMITING;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; GRANISETRON; HUMANS; NAUSEA; QUALITY OF LIFE; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0029923372     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609040-00009     Document Type: Review

References (93)

1. Bliss JM, Robertson B, Selby PJ. The impact of nausea and vomiting upon quality of life measures. Br J Cancer 1992 Dec; 66 Suppl. 19: S14-23
2. Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-8
3. Love RR, Leventhal H, Easterling DV, et al. Side effects and emotional distress during cancer chemotherapy. Cancer 1989; 63: 604-12
4. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988; 6: 1746-52
5. Lindley CM, Hirsch JD. Nausea and vomiting and cancer patients' quality of life: a discussion of Professor Selby's paper. Br J Cancer 1992 Dec; 66 Suppl. 19: S26-29
6. Lindley CM, Hirsch JD, O'Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992 Oct; 1: 331-40
7. Joss RA, Brand BC, Buser KS, et al. The symptomatic control of cytostatic drug-induced emesis. A recent history and review. Eur J Cancer 1990; 26 Suppl. 1: S2-8
8. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983; 25 (1) Suppl. 1: 1-7
9. Penta J, Poster D, Bruno S. The pharmacologic treatment of nausea and vomiting caused by cancer chemotherapy: a review. In: Laszlo J, editor. Antiemetics and cancer chemotherapy. Baltimore: Williams and Wilkins, 1983: 53-92
10. Aapro MS. A framework for assessing therapeutic innovation. Anticancer Drugs 1993; 4 Suppl. 3: 27-31
11. Boakes RA, Tarrier N, Barnes BW, et al. Prevalence of anticipatory nausea and other side-effects in cancer patients receiving chemotherapy. Eur J Cancer 1993; 29A: 866-70
12. Morrow GR. Prevalence and correlates of anticipatory nausea and vomiling in chemotherapy patients. J Natl Cancer Inst 1982 Apr; 68: 585-8
13. Eisenberg PD. Further profiles of granisetron (Kytril): effect on quality of life and pharmacoeconomics. Semin Oncol 1994 Jun; 21 Suppl. 5: 26-9
14. Goddard M. The real costs of emesis. Eur J Cancer 1993; 29A (3): 297-8
15. O'Brien BJ, Rusthoven J, Rocchi A, et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. Can Med Assoc J 1993 Aug 1; 149: 296-302
16. Cadman EC, Durivage HJ. Cancer Chemotherapy. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principles of internal medicine. 12th ed. New York: McGraw-Hill Inc., 1991: 1587-99
17. Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1992: 1 (1): 20-32
18. Kirchner V. Clinical studies to assess the economic impact of new therapies: pragmatic approaches to measuring costs. Anticancer Drugs 1993 Dec; 4 Suppl 3: 13-20
19. Plosker GL, Milne RJ. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. PharmacoEconomics 1992 Oct; 2: 285-304
20. 3 antagonists as first line antiemetic therapy in cisplatin-based chemotherapy?'. Ann Oncol 1993 May; 4: 434-5
21. Yarker YE, McTavish D. Granisetron: an update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994 Nov; 48: 761-93
22. Ninane J, Ozkaynak MF, Kurtin P, et al. Variation in the use of ondansetron as an antiemetic drug in children treated with chemotherapy. Med Pediatr Oncol 1995 Jul: 25: 33-7
23. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994 Oct; 12: 2204-10
24. Rivierre A on behalf of the Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994; 69: 967-71
25. Anon. 1995 Physicians GenRx. 5th ed. Riverside (CT): Mosby-Year Book Inc., 1995
26. SmithKline Beecham. Granisetron prescribing information. Physicians' desk reference. 49th ed. Montvale (NJ): Medical Economics Data Production Company, 1995
27. Glaxo. Ondansetron prescribing information. Physicians' desk reference. 49th ed. Montvale (NJ): Medical Economics Data Production Company, 1995
28. British National Formulary. 30th (Sep 1995) ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1995
29. Lee CR, Plosker GL, Benfield P. Tropisetron: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993 Nov; 46 (5): 925-43
30. Markham A, Sorkin EM. Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993 Jun; 45 (6): 931-52
31. Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Comparisons of ondunsetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995; 76: 343-57
32. Schmoll H-J. The role of ondansetron in the treatment of emesis induced by non-cisplatin containing chemotherapy regimens. Eur J Cancer Clin Oncol 1989; 25 Suppl. 1: S35-39
33. Rubenstein EB, Elting LS. Pharmacoeconomic analyses: whose perspective counts and costs the most? Am J Hosp Pharm 1994 Jun 15; 51: 1564-9
34. Schmoll H-J. Quality of life measurements in anti-emetic trials: a discussion of Professor Selby's paper. Br J Cancer 1992 Dec; 66 Suppl. 19: S24-25
35. Osoba D, Pater JL, Zee B, et al. Effective anti-emetic therapy improves quality of life (QOL) after moderately emetogenic chemotherapy (MEC) [abstract]. Qual Life Res 1995; 4: 467-8
36. Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. Semin Oncol 1994 Jun; 21 Suppl. 5: 15-21
37. Soukop M. Clinical experience with intravenous granisetron. Anticancer Drugs 1994 Jun; 5: 281-6
38. Craft AW, Price L, Eden OB, et al. Granisetron as antiemetic therapy in children with cancer. Med Pediatr Oncol 1995; 25: 28-32
39. Hirota T, Honjo T, Kuroda R, et al. Antiemetic efficacy of graniselron in the treatment of pediatric cancer. (1) Clinical evaluation of granisetron at a dose of 40 micrograms per kilogram [in Japanese]. Gan to Kagaku Ryoho 1993 Nov; 20: 2201-5
40. Hirota T, Honjo T, Kuroda R, et al. Antiemetic efficacy of granisetron in pediatric cancer treatment. (2) Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis [in Japanese]. Gan to Kagaku Ryoho 1993 Dec; 20: 2369-73
41. Jacobson SJ, Shore RW, Nishimura L, et al. Efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anti-cancer chemotherapy [abstract]. Eur J Cancer 1991; 27 Suppl. 2: S257
42. Jacobson SJ, Leclerc JM, Conn RJ, et al. Intravenous granisetron in children receiving highly emetogenic chemotherapy: a double blind, dose-ranging study. Eur J Clin Res 1995; 7: 145-54
43. Lemerle J, Amaral D, Southall DP. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients. Eur J Cancer 1991 Sep; 27: 1081-3
44. Miyajima Y, Numata S-I, Katayama I, et al. Prevention of chemotherapy-induced emesis with granisetron in children with malignant diseases. Am J Pediatr Hematol Oncol 1994 Aug; 16: 236-41
45. Zucker JM, Quintana E, Hahlen K, et al. IV granisetron in children: a randomized comparative study [abstract no. 1619]. Proc Am Soc Clin Oncol 1993; 12: 465
46. Hesketh P. Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Semin Oncol 1995 Aug; 22 (4) Suppl. 10: 19-23
47. Perez EA. Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy-induced nausea and vomiting. Semin Oncol 1995 Aug; 22 (4) Suppl. 10: 1-2
48. Chevallier B, The Granisetron Study Group. The control of acute cisplatin-induced emesis - a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 1993 Jul; 68: 176-80
49. Warr D, Wilan A, Venner P, et al. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis: an NCI Canada Clinical Trials Group Phase III Trial. Eur J Cancer 1993 Oct; 29A (1): 33-6
50. Marty M. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. Eur J Cancer 1992; 28A Suppl. 1: 12-6
51. Bremer K. A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. Eur J Cancer 1992 May; 28A: 1018-22
52. The Granisetron Study Group. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. J Cancer Res Clin Oncol 1993; 119: 555-9
53. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805-10
54. Mantovani G, Maccio A, Curreli L, et al. Comparison of the effectiveness of three 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13: 428
55. Martoni A, Angelelli B, Guaraldi M, et al. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cis-platinum-induced emesis: an open randomized cross-over study [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 431
56. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995 May; 13: 1242-8
57. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994 Jan-Feb: 51: 113-8
58. Bonneterre J, Hecquet B, on behalf of the French Northern Oncology Group. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy: a crossover study. Eur J Cancer Clin Oncol. In press
59. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting: results of a prospective randomized trial. Cancer 1994 Oct 1; 74: 1945-52 [Summary in 2 parts (Pt A)]
60. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study Eur J Cancer 1993; 29A (12): 1669-72
61. Stewart A, McQuade B, Cronje JD, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology 1995 May-Jun; 52: 202-10
62. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994; 30A (8): 1083-8
63. Roila F, Tonato M, Basurto C, et al. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 1989; 7: 1693-700
64. Martin MM, Diaz-Rubio E, Casado A, et al. Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy. Eur J Cancer Clin Oncol 1992; 28: 430-2
65. Italian Group for Antiemetic Research. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993; 11: 2396-2404
66. Italian Group for Antiemetic Research. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 1995; 13: 2417-26
67. Carmichael J, Bessel EM, Harris AL, et al. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer 1994 Dec; 70: 1161-4
68. Heron JF, Goedhals L, Jordaan JP, et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1994 Sep; 5: 579-84
69. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer 1995; 3: 307-12
70. Roila F, Ballatori E, De AV. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995 Jan 5; 332: 1-5
71. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind randomised trial comparing placebo, dexamethasone alone, and metoctopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7 (1): 108-14
72. Kris MG, Pisters KMV, Linda H. Delayed emesis following anticancer chemotherapy. Support Care Cancer 1994; 2: 297-300
73. Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 1991; 14 (3): 238-42
74. 3 receptor antagonists: a retrospective comparison of ondansetron and granisetron. Anticancer Drugs 1995 Apr; 6: 243-9
75. Jobet I, Zyguel S, Prugnaud JL. Exonomic evaluation of anti-5HT3: development of an economic model for cost minimisation study [in French]. J Pharm Clin 1995 Mar; 14: 55-63
76. Kirchner V, Aapro M, Alberto P, et al. The cost effectiveness of granisetron compared to metoclopramide with dexamethasone [abstract no. 1315]. Proc Am Soc Clin Oncol 1992 Mar; 11: 379
77. Kirchner V, Aapro M, Terrey J-P. Antiemetic treatment costs in chemotherapy; the economic evaluation of granisetron [abstract]. Ann Oncol 1992 Nov; 3 Suppl. 5: 185
78. Aapro MS, Kirchner V, Terrey JP. The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer 1994 May; 69: 957-60
79. Berard CM, Mahoney CD. Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Am J Health Syst Pharm 1995; 52: 1879-85
80. Bressolle F, Bons F, Coste E. et al. Pharmacist development and use of antiemetic protocols [letter]. Am J Health Syst Pharm 1995; 52: 319-20
81. Chetcuti N, Peacocke G, Ezzy J, et al. Development of guidelines for ondansetron use [abstract]. Aust J Hosp Pharm 1993 Feb; 23: 54
82. Dranitsaris G, Puodziunas A, Warr D. A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer 1995; 3: 183-9
83. Ezzy JA, Chetcuti NL, Peacocke GH, et al. Drug utilisation review of ondansetron in four Sydney metropolitan hospitals. Aust J Hosp Pharm 1993 Oct; 23: 312-7
84. Foot AB, Hayes C. Audit of guidelines for effective control of chemotherapy and radiotherapy induced emesis. Arch Dis Child 1994 Nov; 71: 475-80
85. Gannon RH, Wallace MJ. Cost and efficacy based program to manage the use of granisetron and ondansetron in oncology patients [abstract]. Pharmacotherapy 1995 Jan-Feb; 15: 122
86. 3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer 1993 Oct; 29A (1): 51-6
87. Vermeulen Jr LC, Matuszewski KA, Ratko TA, et al. Evaluation of ondansetron prescribing in US academic medical centers. Arch Intern Med 1994 Aug 8; 154: 1733-40
88. Walton SC, Koenig TJ. Effectiveness and economy of low-dose ondansetron [letter]. Am J Health Syst Pharm 1995 Mar 1; 52: 546-7
89. Zbrozek AS, Cantor SB, Cardenas MP, et al. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994 Jun 15; 51: 1555-63
90. Coates A, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 1992; 10: 1833-8
91. Bosanquet N. The costs of health care: implications for antiemetic therapy. Anticancer Drugs 1993; 4 Suppl. 3: 9-12
92. Blum KV, Abel SR, Urbanski CJ, et al. Medication error prevention by pharmacists. Am J Hosp Pharrn 1988 Sep; 45: 1902-3
93. Reid LD, McKenna DA, Horn JR. Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring. Am J Hosp Pharm 1989 May; 46: 945-51